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The NMDA subtype of ionotropic glutamate receptors requires occupation by both rghttamate and the co-agonist glycine for efficient channel 
opening. To elucidate the role of disuhide bridges for the allosteric interaction of these agonists we mutated the cysteine residues in the 
ligand-binding NMDARl (NRl or %) subunit of the rodent NMDA receptor and co-expressed the resulting mutants with the NRZB (~2) subunit 
in Xenopus oocytes. Most of the cysteine substitutions had no effect on agonist responses. However, replacement ofcysteines 402 and 418 by alanine 
largely abolished the potentiation of glutamate currents by glycine. These cysteine residues in the putative extracellular domain of the NRl subunit 
may form a disulfide bridge important for agonist interaction. 
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1. ~RODU~ION 
The amino acid glutamate is the major excitatory 
neurotransmitter in the vertebrate central nervous sys- 
tem. Its postsynaptic actions are mediated by a diverse 
set of specific receptors, which have been implicated in 
brain development, synaptic plasticity, memory forma- 
tion and neurotoxicity [l-3]. Amongst these, the N- 
methyl-D-aspartate (NMDA) receptor has gained par- 
ticular attention, since this l&and-gated ion channel is 
highly permeable to Ca*’ ions and blocked in a voltage- 
dependent manner by MC ions 141. These properties 
are thought to provide the molecular basis for activity- 
dependent adaptation mechanisms including long-term 
potentiation and heterosynaptic depression [5]. In addi- 
tion, both glutamate and glycine are required for effi- 
cient channel activation of the NMDA receptor [6,7]. 
This dual regulation of NMDA receptor function un- 
derlines the role of this membrane protein as a postsyn- 
aptic coincidence detector [I,21 and may be important 
for the modulation of synaptic efficacy [2,5]. 
The first cDNA encoding a NMDA receptor protein 
was isolated by expression cloning [8]. When singly ex- 
pressed in Xenupus oocytes, this NMDARl (NRl or 5; 
see @--11] for nomenclature) subunit generates chan- 
nels, which display most of the typical pharmacology of 
the native NMDA receptor. In particular, significant 
current responses are only seen upon co-application of 
glutamate and glycine, and these currents are readily 
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blocked by Mp ions [8,9]. However, the maximal cur- 
rent responses obtained from these homo-oligomeric 
NRl channels are small, but strongly increase upon 
co-expression of a member of a second family of 
NMDA receptor proteins, the NR2 (or &) subunits [lO- 
131. The NR2 subunits do not generate detectable cur- 
rents upon single expression, but strongly potentiate 
NRl responses upon co-expression. Based on these 
data, the NRl and NR2 subunits can be classified as 
ligand-binding and structural subunits, respectively, of 
the mammalian NMDA receptor. 
Pharmacological and electrophysiological studies in- 
dicate that glutamate and glycine bind to distinct sites 
of the NMDA receptor [6,7,14,15]. The mechanism of 
glycine potentiation of glutamate currents is not entirely 
clear, but may involve allosteric modulation of agonist 
binding affinities in addition to changes in desensitiza- 
tion kinetics [ 16,171. To elucidate the molecular basis of 
these agonist interactions, we performed in vitro mut- 
agenesis of the ligand-binding NRl subunit. Here, we 
show that two cysteine residues, cysteine 402 and cyste- 
ine 418, are important for the potentiation of glutamate 
currents by glycine. Our data suggest hat a disulfide 
bridge formed between these residues may be crucial for 
cooperative gating of the NMDA receptor by glutamate 
and glycine. 
2. MATERIALS AND METHODS 
2.1. In vitro mutagenesis 
Oligonucleotide-~~~ mu~gen~is was performed with single- 
stranded DNA of clone pN60 (NRI cDNA, see [S]), or of a yPnI/SucI 
fragment (bp 13742327) thereof, using commercial kits (in vitro Mut- 
agenesis System II, Amersham, and Muta-Gene Phagemid in vitro 
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Mutagenesis Kit, BioRad). The tripletts encoding cysteine residues 4, 
61, 290, 402, 418, 436, 437, 441, 726 and 780 of the mature NRI 
subunit were substituted by alanine or other amino acid codons, re- 
spectively (see Fig. 1). All mutations were verified by dideoxy sequenc- 
ing (181. Mutant designations use the IUPAC single-letter amino acid 
code, with the letter preceding the position number referring to the 
wild-type residue, and the letter after the number corresponding to the 
amino acid replacing the former. 
2.2. c&VA synthesis and oocyte expression 
Linearized plasmid DNAs were used for the in vitro synthesis of 
cRNA (mCAP?nRNA Capping Kit, Stratagene). cRNAs of the rat 
NRl[8] and the mouse NR23 [12] subunits were synthesized using T7 
or T3 RNA polymerases, respectively. cRNA concentrations were 
determined by both measuring the optical density at 260 nm and 
comparing Methylene blue staining intensities after gel electrophore- 
sis. For oocyte injection, the concentration of the cRNA samples was 
adjusted to 200-500 n&l. For co-expression experiments, appropri- 
ately diluted aliquots of the NR1 and NR2B cRNAs were mixed 
before injection to achieve an RNA ratio of 1:l. Microinjection of 
about 50 nl cRNA into Xenopus laevb oocytes and voltage clamp 
recording of agonist responses in Me-free frog Ringer’s solution at 
a holding potential of -70 mV were performed as described [19]. 
3. RESULTS AND DISCUSSION 
To investigate the role of disulfide bridges in agonist 
binding to the NMDA receptor, we used site-directed 
mutagenesis to replace the cysteine residues of the NRl 
subunit (Fig. 1) by alanine or, in a few cases, other 
amino acid residues. The mutant proteins were then 
co-expressed with the NR2B subunit using the Xenopus 
oocyte system, and responses to glutamate and the co- 
agonist glycine were measured using two-electrode volt- 
age-clamp recording in the absence of h/IF ions. Peak 
inward currents (I_) obtained with ~turating concen- 
trations of L-glutamate in the presence of 10 PM glycine 
were in the range of loo@-3600 nA for the hetero-oli- 
gomeric wild-type and most of the mutant receptors 
(Table I). However, some cysteine substitutions resulted 
in significantly reduced ion fluxes: CXOZA, 40 + 14 nA; 
C418A, 160 f 100 nA; C418F, 25 z!z 7 nA; and C418S, 
53 + 24 nA. Three mutants, NRlC41sL, NRlC436D and 
NR1C437R, were non-functional (Table I). In conclusion, 
replacement of the cysteines at positions 402 and 418 of 
the NRl subunit caused a strong decrease in NMDA 
receptor current. 
To reveal whether this decrease could be attributed 
to changes in ligand binding, dose-response relations of 
the mutant NMDA receptors were examined for L-glu- 
tamate in the presence of 10 PM glycine and for glycine 
in the presence of 10 PM L-glutamate. Under these con- 
ditions, the agonist concentrations eliciting a half-maxi- 
mal response (EC,,) varied from 0.7 to 3.0 PM for 
rglutamate, and from 0.25 to 0.73 ,uM for glycine, 
respectively, with all mutants tested (Table I). These 
values are similar to those of the wild-type NRl/NR2B 
hetero-oligomeric hannel, indicating that the low cur- 
rent responses of the cysteine 402 and cysteine 418 sub- 
stitutions were not caused by a reduction of agonist 
binding affinities. 
All hetero-oligomeric wild-type and mutant channels 
Table I 
Fictions and pha~acolo~c~ properties of NRI cysteine mutants 
NRl mutant 
EC,, OW Lx @A) Potentiation I& #M) 
L-Glutamate Glycine (-fold) 7-Chlorokynurate 
Wild-type 1.5 f 0.5 0.52 + 0.3 3.6 ?L: 1.0 62.0 zt 30.0 0.6 It 0.3 
COO4A 2.8 * 0.9 0.43 2 0.3 2.3 + 1.1 33.6 2 25.0 0.9 * 0.5 
CO61A 1.1 Z!Z 0.5 0.25 + 0.2 1.0 * 0.25 36.2 + 19.0 0.5 + 0.2 
C290A 1.5 + 0.3 0.35 r 0.1 2.2 * 0.7 65.5 + 21.0 0.6 f 0.3 
C402A 3.0 + 1.2 0.47 It 0.4 0.04 + 0.014 3.5 + 0.5 2.0 + 0.3 
c418A 2.8 f 0.9 0.68 + 0.3 0.16 rt 0.1 4.5 + 4.1 0.8 ?1 0.4 
C418L _ _ NF - 
c418F ND ND 0.025 + 0.007 4.0 + 0.9 NT 
C418S 3.0 & 0.8 0.72 + 0.2 0.053 + 0.024 5.7 f 4.0 NT 
C436A 1.3 f 0.9 0.48 f 0.2 1.2 rt 0.5 NT 0.5 f 0.2 
C436D _ _ NF - 
C436S 1.7 f 0.5 0.73 -I 0.3 2.7 If: 1.2 54.8 + 26.0 0.8 IO.1 
C437A l.Of0.6 0.70 f 0.4 3.2 ?: 1.0 NT 1.0 * 0.8 
C437R 
3.0 I 1.2 
_ NF - 
c437s 0.25 + 0.1 1.6 to.1 55.3 + 25.0 C 41A f 0 5 4 f 0 95 rt 0.5 26 8rt 13.  0.5lYO.l 
C726A 0.7 f 0.3 0.25 & 0.1 3.3 ?; 1.1 15.2 + 4.3 0.9 2 0.5 
C780A 0.7 + 0.2 0.41 + 0.3 3.1 i: 0.9 17.3 + 3.8 1.4f 1.0 
NRl wild-type and mutant cRNAs were coinjected into Xenopus oocytes, and the receptors generated analyzed by voltage clamp recording as 
detailed under Material and Methods. EC& values f S.D. were calculated from dose-response curves obtained from 3-9 oocytes, each. IC,, values 
were measured at the EC& value of glycine in the presence of 10 PM L-glutamate on 2-4 oocytes. Non-functional mutants were tested in 2 10 
oocytes. Im. values were determined in the presence of saturating concentrations of L-glutamate and glycine, respectively. Potentiation of the 
responses evoked by single apportion of 10 PM L-glutamate and 10 PM glycine indicates the relative increase in total current seen upon 
coapplication of both agonists. ND - not determined because of low channel activities; NF - non-functional; NT - not tested. 
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Fig. 1. Schematic representation of the NRl subunit. Predicted membrane spanning regions (Ml to M4) are symbolized by boxes. The cysteines 
mutated in this study are indicated by arrows; numbers correspond to amino acid positions in the mature protein. A non-mutated cysteine in the 
very C-terminal region of the protein is indicated by a triangle. 
displayed small current responses when challenged with 
10 PM L-glutamate or glycine alone (Fig. 2A, and data 
not shown). With wild-type NRl/NR2B channels, the 
responses evoked by single agonist application were 
strongly (ca. 60-fold) enhanced upon co-application of 
both agonists (Fig. 2A, B). Similar results were obtained 
for the cysteine substitutions at positions 4,61,290,436, 
437 and 441 of the NRl subunit (Table I). However, 
channels generated from the NR1cmzA and NRlC41sA 
mutant proteins showed only small increases in total 
current upon superfusion of both glutamate and glycine 
(Fig. 2 and Table I). Thus, cysteines 402 and 418 appear 
to be crucial for the cooperative gating of the NMDA 
receptor by glutamate and glycine. Interestin~y, the 
NR 1 c726A and NR 1 “‘OA mutants also showed a signifi- 
cantly reduced glycine potentiation upon co-expression 
(Table I). This may indicate that the corresponding po- 
sitions between the third and fourth transmembrane 
segment are localized on extracellular domains of the 
NMDA receptor. Recent models of ~utamate receptor 
subunit topology are consistent with this interpretation 
POI. 
Kynurenic acid and its derivatives are potent compet- 
itive antagonists of the glycine modulatory site of the 
NMDA receptor [21]. We therefore tested whether 7- 
chlorokynurenic acid inhibits mutant glutamate re- 
sponses in the presence of glycine. For all NRl cysteine 
substitutions producing a response, the concentrations 
of 7-chlorokynurenic acid causing half-maximal inhibi- 
tion (IC,,) ranged between 0.5 to 2.0 ,uM, i.e. close to 
the IC,,, value of the hetero-oligome~c wild-type recep- 
tor (Table I). This supports the view that the C402A and 
C418A mutations do not affect the properties of the 
glycine binding site, but disrupt glycine-glutamate in- 
teraction. 
What might be the role of these cysteines in the co- 
operative gating of the NMDA receptor? In our view, 
the simplest explanation is that cysteines 402 and 418 
form a disulfide bridge essential for conformational 
transitions induced upon agonist binding. Interestingly, 
a disuhide-bonded loop of similar size, e.g. covering 15 
amino acid residues, is found in the N-terminal extracel- 
lular domain of other neurotransmitter-gated ion chan- 
nel proteins, e.g. the subunits of the excitatory nicotinic 
3000 
1 q NA1”“A/NR2B T 
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agonist applied 
Fig. 2. Agonist responses of hetero-oiigomeric NMDA receptors generated by functional co-expression of wild-type and mutant NRl subunits with 
the NRZB polypeptide. Xenopus oocytes were injected with the cRNAs, and agonist responses were recorded as described in Section 2. (A) Inward 
current responses to 10 yM L-glutamate, 10 PM glycine and 10 ,uM L-glutamate plus 10 fluM glycine of channels containing the wild-type NRl, 
or the mutant NRIWW and NRlC4’“, subunits. The duration of agonist application is indicated by bars. (B) Mean agonist responses of the 
hetero-oligomeric NRl/NRZB and the mutant NRlWU/NR2B and NRl W1sA/NR2B receptors. Note that the large potentiation of the glutamate 
current by glycine seen with the wild-type receptor is largely abolished upon cysteine substitution. The data represent the mean + S.D of 3-9 oocytes. 
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acetylcholine and serotonine (type 3) receptors and of 
the inhibitory GABA,, and glycine receptor proteins 
[22,23]. For the nicotinic a~tylcho~e and glycine re- 
ceptors, substitution of the flanking cysteine residues 
has been shown to strongly reduce the expression of 
functional channels [24-261, although this conserved di- 
sulfide loop region is known not to participate in ag- 
onist binding [25,27,28]. We therefore speculate that 
such disulfide bridges in the extracellular domain of ion 
channel forming receptors may provide folding pat- 
terns, which allow for rapid conformational changes 
elicited by ligand binding. 
Previous electrophysiological work has shown that 
the native NMDA receptor has a redox modulatory site 
thought to consist of vicinal thiol groups, whose reduc- 
tion increases current flux through the receptor channel 
without affecting glutamate-glycine interaction [29,30]. 
In the nicotinic acetylcholine receptor, two neighbour- 
ing cysteine residues preceding the first transmembrane 
segment have been found to be in close proximity to 
bound a~tylcholine [31]. A similar pair of cysteines 
exists in the NRl subunit at positions 436 and 437. In 
our hands, substitution of these residues by alanine or 
serine had no significant effect on agonist affinities and 
glycine potentiation (Table I). However, the incorpora- 
tion of charged residues at these positions in mutants 
NR 1 c436D and NRl C437R rendered the channel non-func- 
tional. We interpret this as evidence for a structural role 
of these residues rather than their participation in ligand 
binding. Recent mutagenesis experiments from our lab- 
oratory show that side chains other than cysteines are 
important for agonist binding to the NMDA receptor 
(A. Kuryatov, B. Laube, H. Betz and J. Kuhse, in prep 
aration). 
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